Cargando…
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib...
Autores principales: | Yang, Eric H., Courtney, Cynthia, Garg, Vinisha, Fradley, Michael G., Schiller, Gary J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048019/ https://www.ncbi.nlm.nih.gov/pubmed/32154003 http://dx.doi.org/10.1186/s40959-018-0028-z |
Ejemplares similares
-
High Intensity Exercises in Heart Failure with Preserved Ejection
Fraction
por: Herdy, Artur Haddad, et al.
Publicado: (2018) -
Minimal subphenotyping model for acute heart failure with preserved ejection fraction
por: Sotomi, Yohei, et al.
Publicado: (2022) -
Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction
por: D'Assante, Roberta, et al.
Publicado: (2021) -
Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction
por: Tanacli, Radu, et al.
Publicado: (2020) -
Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)